



WHITE PAPER

# SAIZ TOKEN

Special Anti-Virus Innovation Zone

---

Blockchain | Biotechnology | Global Health

SAIZ (CNX-20) Token · Cofinex Exchange · 50,000,000 Supply

[www.saizone.ai](http://www.saizone.ai)

Version 1.0 · 2026 · Republic of Korea

⚠ This document is for informational purposes only and does not constitute investment advice or a securities offering. Please read the full Legal Disclaimer in Section 13.

## ◆ Table of Contents

---

1. Executive Summary
2. The Pandemic Problem & Market Opportunity
3. Technology & Oral Antibody Innovation
4. The SAIZ Ecosystem & Revenue Model
5. Tokenomics & Token Details
6. Token Distribution & Vesting Schedule
7. Use of Funds
8. Project Roadmap (2025–2028)
9. Team & Advisors
10. Partnerships & Collaborators
11. Exchange Listing & Payment Infrastructure
12. Governance & Community
13. Legal Disclaimer & Regulatory Compliance
14. Contact & Community

## ◆ 1. Executive Summary

SAIZ Token (Special Anti-Virus Innovation Zone Token) is a CNX-20 standard digital asset issued on the Cofinex blockchain ecosystem, purpose-built to finance and accelerate the global commercialization of 'oral antibody' technology — a transformative biotechnology innovation in the fight against pandemic-level viral threats.

SAIZ bridges two of the most critical domains of our time: global public health and decentralized financial technology. By anchoring token value to real-world biotechnology royalty revenues, SAIZ offers investors and community members a rare combination of social purpose and commercial potential.

The project is anchored by a formal Asian licensing agreement with Loa Biopharm Co., Ltd. (loabiopharm.com), a globally recognized antibody raw material supplier & biolumen (biolumen.com). This agreement grants SAIZ exclusive royalty rights to a standardized rotavirus oral antibody across Asian markets — most critically, the massive and rapidly growing Indian healthcare market.

With a hard-capped supply of 50,000,000 SAIZ tokens, a robust decentralized governance model, real-world payment utility via the Copay card (Cofinex), and an educational ecosystem through the Happy Blockchain Academy (HBA), the SAIZ project is engineered for long-term, sustainable value creation.

**50,000,000**

Total SAIZ Supply (Fixed — No Inflation)

**440,000+**

Annual Infant Deaths from Rotavirus (Target Market)

**50%+**

Avian Flu Fatality Rate (Secondary Target)

## ◆ 2. The Pandemic Problem & Market Opportunity

### 2.1 What Is a Pandemic?

A pandemic is declared by the World Health Organization (WHO) when an infectious disease spreads rapidly across international borders, affects populations worldwide, and requires urgent coordinated global response. It represents the highest-tier public health emergency classification.

Climate change, accelerated global travel, and increasing human-animal interface are converging to shorten the intervals between outbreaks. Experts widely agree: the question is not whether the next pandemic will occur — but when.

### 2.2 Historical Pandemic Events

Since the WHO's establishment in 1948, three official global pandemics have been declared:

- 1968 — Hong Kong Flu (H3N2): A global influenza pandemic causing an estimated 1–4 million deaths worldwide.
- 2009 — H1N1 Influenza (Swine Flu): Spread to over 214 countries within months of emergence; estimated 151,000–575,000 deaths in the first year.
- 2020 — COVID-19: The most disruptive pandemic in a century, causing over 7 million confirmed deaths globally and trillions of dollars in economic damage.

### 2.3 The Zoonotic Threat Landscape

Beyond declared pandemics, humanity faces a relentless series of dangerous zoonotic (animal-to-human) outbreaks. Approximately 80% of all emerging infectious diseases are zoonotic in origin — including COVID-19 itself.

Year	Disease	Key Characteristics	Fatality Rate
2002	SARS	Novel coronavirus; rapidly controlled via quarantine	~10%
2012	MERS	Camel-to-human transmission; severe respiratory illness	~34%
2013	SFTS Virus	Tick-borne; severe fever with thrombocytopenia	~12–30%
2014	Ebola	Hemorrhagic fever; high mortality in West Africa	~50%
2017	Zika Virus	Linked to microcephaly and Guillain-Barré syndrome	<1% (but severe birth defects)
2024–	H5N1 Avian Flu	Active pandemic threat; zoonotic spillover accelerating	50%+

## 2.4 Market Opportunity

The global market for antiviral therapeutics and vaccines is projected to exceed USD 105 billion by 2030, driven by post-pandemic awareness, increased public health funding, and rising demand for accessible, affordable solutions in emerging economies.

Rotavirus alone represents a critical unmet need: 440,000 children under five die from rotavirus-associated dehydration every year, the overwhelming majority in low- and middle-income countries. India accounts for a disproportionate share of this burden, making it the single most important commercial market for SAIZ's initial product offering.

## ◆ 3. Technology & Oral Antibody Innovation

### 3.1 What Are Oral Antibodies?

Antibodies (immunoglobulins) are specialized proteins produced by the immune system to neutralize pathogens. Traditional passive immunization requires injected antibody preparations — a process that demands cold-chain logistics, trained medical personnel, and sterile equipment, making large-scale deployment in developing regions costly and logistically complex.

Oral antibody technology — the scientific and commercial cornerstone of the SAIZ ecosystem — delivers functional antibodies through ingestion. By engineering antibodies to survive the digestive environment and retain neutralizing activity in the gastrointestinal tract, oral antibodies can be administered without injections, making them dramatically more accessible for mass deployment.

Oral antibody technology has the potential to democratize passive immunization — making life-saving antiviral protection available to populations who have historically been unreachable by conventional vaccine infrastructure.

### 3.2 Technology Partner: LOA Biopharm Co., Ltd.

The foundational antibody technology and raw materials within the SAIZ ecosystem are supplied by **LOA Biopharm Co., Ltd.** (loabiopharm.com), the **exclusive global supplier of antibody raw materials**. LOA Biopharm is a globally recognized manufacturer and distributor of high-purity antibody raw materials, in collaboration with Biolumen (bio-lumen.com).

LOA Biopharm and Biolumen's proprietary processes enable the production of oral-compatible antibodies at commercial scale.

SAIZ has entered into a formal Asian licensing agreement with LOA Biopharm and Biolumen for a standardized rotavirus antibody, establishing an ongoing royalty revenue stream that directly underpins the SAIZ token ecosystem's financial model.

### 3.3 Primary Target: Rotavirus

Rotavirus is the leading global cause of severe diarrheal disease in children under five years of age. Despite the existence of injectable vaccines, coverage in high-burden regions remains inadequate due to cost, cold-chain requirements, and healthcare access barriers. An affordable, easily-administrable oral antibody solution has the potential to save hundreds of thousands of lives annually.

### 3.4 Secondary Target: Avian Influenza (H5N1)

H5N1 Avian Influenza represents one of the most feared pandemic-potential pathogens known to science, with a documented human case fatality rate exceeding 50%. As spillover events from poultry and wild bird populations increase globally, the development of effective, accessible antiviral countermeasures is considered an urgent priority by the WHO and national health agencies worldwide.



## ◆ 4. The SAIZ Ecosystem & Revenue Model

---

### 4.1 Core Revenue Engine: Antibody Licensing Royalties

The SAIZ ecosystem is fundamentally distinguished from speculative token projects by its grounding in tangible, recurring, real-world revenue. The Asian licensing agreement with Loa Biopharm & Biolumen entitles SAIZ to royalty payments derived from the commercialization of the standardized rotavirus oral antibody across Asian markets.

This revenue model provides:

- **Recurring Cash Flow:** Royalties accrue on an ongoing basis as the antibody product is distributed and sold.
- **Scalable Revenue:** As Indian and broader Asian market penetration grows, royalty income scales accordingly.
- **Token Value Anchor:** Royalty revenues provide a fundamental value anchor for the SAIZ token, reducing dependence on speculative trading sentiment.

### 4.2 India Market Strategy

India represents the highest-priority commercial target for SAIZ's rotavirus antibody product. India carries one of the world's highest burdens of rotavirus disease, with millions of infants hospitalized annually and tens of thousands dying. Key market drivers include:

- **Population Scale:** India has approximately 25 million births per year — a vast addressable market for infant health products.
- **Healthcare Expansion:** India's healthcare sector is growing at 22% CAGR, with significant government investment in public health infrastructure.
- **Affordability Gap:** Existing rotavirus vaccine solutions remain cost-prohibitive for large segments of the Indian population, creating a clear opportunity for a more affordable oral antibody alternative.
- **Regulatory Environment:** India's CDSCO (Central Drugs Standard Control Organisation) has established pathways for biologics and antibody products that SAIZ will navigate in partnership with Loa Biopharm.

### 4.3 Happy Blockchain Academy (HBA)

The Happy Blockchain Academy (HBA) is SAIZ's global blockchain education initiative. HBA supports voluntary, self-organizing blockchain communities worldwide, providing structured educational programs designed to:

- Expand global blockchain literacy and adoption.
- Empower underserved communities to participate in the digital economy.
- Build a committed, knowledgeable SAIZ community that drives long-term ecosystem growth.

A defined allocation of SAIZ ecosystem profits is directed toward HBA operations, embedding social impact into the project's financial architecture.

## ◆ 5. Tokenomics & Token Details

### 5.1 Core Token Parameters

<b>Token Name</b>	SAIZ — Special Anti-Virus Innovation Zone Token
<b>Token Standard</b>	CNX-20 (Cofinex Blockchain)
<b>Total Supply</b>	50,000,000 SAIZ (Hard Cap — No Additional Issuance Ever)
<b>Blockchain</b>	Cofinex (CNX-20) — cofinex.io
<b>Initial Exchange</b>	Cofinex.io (India)
<b>Early Bird Sale Price</b>	USD \$0.97 per SAIZ
<b>Public Sale Price</b>	USD \$1.20 per SAIZ
<b>Target Listing Price</b>	USD \$1.50 per SAIZ
<b>Project Jurisdiction</b>	Republic of Korea
<b>Website</b>	www.saizone.ai

### 5.2 Token Utility

SAIZ is a multi-utility governance token. Its utility spans the following functions within the ecosystem:

Utility	Description
Governance Rights	Token holders vote on key project decisions including partnerships, fund allocation, roadmap priorities, and ecosystem updates via decentralized voting mechanisms.
Staking Rewards	SAIZ holders can stake tokens to earn passive rewards, paid from ecosystem revenue. Staking reduces circulating supply and incentivizes long-term holding.
Loyalty Program	Dedicated holders receive exclusive benefits including bonus allocations, early access to new ecosystem features, and tiered reward structures based on holding duration.

Utility	Description
Royalty Revenue Share	A portion of antibody licensing royalty revenues is redistributed to eligible SAIZ stakers, creating a direct link between real-world business performance and token holder returns.
HBA Ecosystem Access	SAIZ holders gain privileged access to HBA educational programs, community events, and blockchain certification pathways.
Copay Card Payment	SAIZ tokens are accepted as a payment method via the integrated Copay card, enabling real-world spending at compatible merchants globally.
Ecosystem Participation	SAIZ tokens grant access to future SAIZ ecosystem products, services, and partner platform integrations as the project expands.

## ◆ 6. Token Distribution & Vesting Schedule

### 6.1 Distribution Breakdown

The 50,000,000 SAIZ token supply is allocated across six categories, designed to balance immediate liquidity needs with long-term ecosystem sustainability and team commitment.

Allocation Category	%	SAIZ Tokens	Lock-up / Vesting
Public Sale	30%	15,000,000 SAIZ	No lock-up. Released at TGE.
Ecosystem & Rewards	25%	12,500,000 SAIZ	Released over 36 months based on ecosystem milestones.
Team & Founders	15%	7,500,000 SAIZ	12-month cliff. 24-month linear vesting thereafter.
Reserve Fund	15%	7,500,000 SAIZ	Locked 24 months. Governance vote required to unlock.
Strategic Investors	10%	5,000,000 SAIZ	6-month cliff. 18-month linear vesting thereafter.
Marketing & Partnerships	5%	2,500,000 SAIZ	Released quarterly over 24 months.
<b>TOTAL</b>	<b>100%</b>	<b>50,000,000 SAIZ</b>	<b>Hard Cap — No Further Issuance</b>

Team and founder tokens are subject to a 12-month cliff followed by 24 months of linear vesting. This structure ensures long-term commitment from core contributors and aligns team incentives with the sustained success of the project and its community.

### 6.2 Vesting Schedule Summary

Category	Cliff Period	Vesting Period	Release Method
Public Sale	None	Immediate (TGE)	100% at Token Generation
Ecosystem & Rewards	None	36 months	Milestone-based releases
Team & Founders	12 months	24 months linear	Monthly after cliff
Reserve Fund	24 months	Governance-controlled	Vote-triggered unlock
Strategic Investors	6 months	18 months linear	Monthly after cliff
Marketing & Partners	None	24 months quarterly	Quarterly tranches

## ◆ 7. Use of Funds

Proceeds raised from the SAIZ token sale will be deployed strategically to maximize ecosystem growth, ensure regulatory compliance, and accelerate the commercialization of the oral antibody product. The allocation is designed to prioritize the activities that generate the greatest long-term value for the SAIZ community.

Allocation Area	% of Funds	Description
Biotechnology R&D	35%	Advancement of oral antibody product development, clinical partnerships, and preparation for regulatory submissions in India and Asian markets.
Business Development & Marketing	25%	Market entry campaigns, partnerships, exchange listings, brand development, community growth, and HBA program funding.
Operations & Infrastructure	15%	Core team salaries, office operations, IT infrastructure, blockchain development, and smart contract audits.
Ecosystem Development	15%	Smart contract ecosystem, DApp development, staking platform, Copay card integration, and governance tooling.
Legal & Regulatory Compliance	7%	Korean legal compliance, international regulatory advisory, IP protection, licensing agreement management, and KYC/AML systems.
Strategic Reserve	3%	Emergency buffer fund for unforeseen operational needs, held in a multi-signature treasury wallet controlled by governance.

All fund allocations are subject to community oversight through SAIZ's decentralized governance mechanism. Token holders may initiate governance votes to review treasury movements above defined thresholds, ensuring full accountability and transparency.

## ◆ 8. Project Roadmap (2025–2028)

The SAIZ project roadmap is organized into four progressive phases, each building upon the foundations of the previous. Timelines reflect realistic execution based on current partnership status, regulatory requirements, and market conditions.

<p><b>Phase 1</b> Q1–Q2 2026</p>	<p><b>Foundation &amp; Launch</b></p> <ul style="list-style-type: none"> <li>Finalize SAIZ token smart contract development and independent security audit on Cofinex CNX-20</li> <li>Publish official Whitepaper v1.0 and project website (www.saizone.ai)</li> <li>Complete formal Asian licensing agreement with Loa Biopharm Co., Ltd.</li> <li>Launch private sale round for strategic investors (price: \$0.97 per SAIZ)</li> <li>Establish legal entity in the Republic of Korea; complete initial regulatory compliance review</li> <li>Build core community: Instagram, Telegram, official channels</li> <li>Appoint legal and medical advisory board</li> </ul>
<p><b>Phase 2</b> Q3–Q4 2026</p>	<p><b>Token Generation &amp; Market Entry</b></p> <ul style="list-style-type: none"> <li>Conduct public token sale (price: \$0.97 per SAIZ); complete KYC/AML procedures</li> <li>Token Generation Event (TGE): Deploy 50,000,000 SAIZ tokens on Cofinex blockchain</li> <li>Official listing on Cofinex.io exchange (target listing price: \$1.50)</li> <li>Activate staking platform and loyalty reward program for token holders</li> <li>Launch Happy Blockchain Academy (HBA) pilot programs in Korea and India</li> <li>Initiate Indian market entry: regulatory pre-submission meetings with CDSCO</li> <li>Begin Copay card integration testing with payment infrastructure partners</li> </ul>
<p><b>Phase 3</b> Q1–Q2 2026</p>	<p><b>Commercialization &amp; Ecosystem Growth</b></p> <ul style="list-style-type: none"> <li>Launch oral rotavirus antibody product in Indian market (B2B distribution)</li> <li>First royalty revenue receipts from Loa Biopharm licensing agreement</li> <li>Activate royalty revenue sharing with eligible SAIZ stakers (first distribution)</li> <li>List SAIZ on second major cryptocurrency exchange (Asia/Global focus)</li> </ul>

- Full launch of Copay card for SAIZ token holders
- Expand HBA educational programs to Southeast Asia and additional markets
- Implement full on-chain decentralized governance (DAO voting platform launch)
- Begin pre-clinical development exploration for H5N1 avian flu oral antibody program

## Phase 4

Q3 2026 – 2028

### Global Expansion & Premium Ecosystem

- Scale Indian rotavirus antibody distribution; expand to Bangladesh, Indonesia, Philippines
- File for additional Asian market regulatory approvals (Japan, Vietnam, Thailand)
- List SAIZ on top-tier global cryptocurrency exchange (Tier 1 target)
- Launch H5N1 avian flu oral antibody program with Loa Biopharm — Phase 1 partnership
- Introduce SAIZ DeFi features: governance-controlled liquidity pool and yield products
- Establish SAIZ Foundation as independent non-profit governance entity
- HBA global expansion: active programs in 20+ countries
- Full transition to community-led DAO governance for all major project decisions

## ◆ 9. Team & Advisors

The SAIZ project is led by an experienced multidisciplinary team spanning biotechnology, blockchain development, international business development, regulatory affairs, and public health. Full team profiles will be disclosed upon completion of KYC procedures and prior to the public token sale.

### 9.1 Advisory Board

SAIZ is advised by a distinguished panel of independent experts across blockchain, public health, and financial regulation. Advisor names and credentials will be disclosed in the project's official channels prior to public sale.

Advisor Role	Domain	Contribution
Blockchain Technical Advisor	DeFi / Smart Contracts	Smart contract audit oversight; DeFi product design advisory
Global Health Advisor	Pandemic Preparedness / WHO	Disease burden analysis; regulatory strategy for antibody products
Financial Regulatory Advisor	Korean FSC / Digital Assets	Korean regulatory compliance; investor relations & reporting
India Market Advisor	Indian Pharmaceutical Market	CDSCO regulatory navigation; Indian distribution partnerships
Investment & Tokenomics Advisor	Digital Asset Investment	Tokenomics structuring; exchange listing strategy; investor relations

## ◆ 10. Partnerships & Collaborators

### 10.1 Loa Biopharm Co., Ltd. — Core Technology Partner

Loa Biopharm (loabiopharm.com) is a globally recognized manufacturer and distributor of high-purity antibody raw materials, with particular expertise in oral-compatible immunoglobulin production. The partnership with Loa Biopharm is the foundational commercial relationship underpinning the entire SAIZ ecosystem.

<b>Partnership Type</b>	Exclusive Asian Licensing Agreement for Standardized Rotavirus Oral Antibody
<b>Territory</b>	Asia (with primary focus on India and South/Southeast Asia)
<b>Revenue Structure</b>	Ongoing royalty payments to SAIZ based on product sales volume
<b>Product</b>	Standardized Rotavirus Oral Antibody — Loa Biopharm proprietary formulation
<b>Website</b>	loabiopharm.com

### 10.2 Cofinex.io — Blockchain & Exchange Partner

Cofinex.io serves as both the SAIZ token's technical blockchain infrastructure (CNX-20 standard) and its primary exchange listing venue. As an India-based exchange with a strong and growing user base, Cofinex provides natural geographic alignment with SAIZ's primary commercial market.

- Technical: SAIZ is a native CNX-20 token on the Cofinex blockchain, benefiting from its security, scalability, and developer ecosystem.
- Commercial: Initial SAIZ token trading will be conducted on Cofinex.io, with additional exchange listings targeted in Phase 3.

### 10.3 Happy Blockchain Academy (HBA) — Education Network

HBA is both a SAIZ initiative and a growing network of independent blockchain education communities across Asia, with expansion targets in Africa, South America, and Europe. HBA communities serve as organic ambassadors and user acquisition channels for the SAIZ ecosystem.

### 10.4 Future Partnerships — Target Categories

SAIZ is actively pursuing additional strategic partnerships in the following domains:

- Indian pharmaceutical distributors and hospital networks for antibody product commercialization.
- Additional Tier-1 and Tier-2 cryptocurrency exchanges for expanded token liquidity.
- Copay card network merchants and financial institutions for payment integration.
- International public health organizations and NGOs for rotavirus and avian flu program support.
- Southeast Asian healthcare distributors for Phase 4 market expansion.

## ◆ 11. Exchange Listing & Payment Infrastructure

### 11.1 Cofinex.io — Primary Exchange

SAIZ will be listed on Cofinex.io at a target price of USD \$1.50 per token following the Token Generation Event (TGE). Key details:

<b>Exchange</b>	Cofinex.io (cofinex.io)
<b>Trading Pair(s)</b>	SAIZ/USDT, (additional pairs subject to exchange agreement)
<b>Listing Price</b>	USD \$1.50 per SAIZ (target)
<b>Listing Timeline</b>	Q2 2026 — Following completion of public token sale
<b>Geographic Focus</b>	India & broader Asian market

### 11.2 Future Exchange Listings

SAIZ's exchange roadmap targets additional listings in subsequent project phases:

- Phase 3 (Q1–Q2 2026): Listing on a second major Asian or global exchange, increasing liquidity and accessibility for international investors.
- Phase 4 (2027): Target listing on a Tier-1 global exchange, marking SAIZ's entry into the premium digital asset category.

### 11.3 Copay Card — Real-World Token Utility

The Copay card is a critical component of SAIZ's real-world utility strategy. Integrated with the SAIZ token wallet, the Copay card allows holders to spend SAIZ tokens as a payment method at any merchant that accepts the Copay network.

This real-world spending utility accomplishes three strategic objectives:

- Increases token velocity and practical demand, creating organic purchasing pressure.
- Provides holders with immediate, tangible utility beyond investment and governance.
- Positions SAIZ as a functional currency within a growing payment network, not merely a speculative asset.

## ◆ 12. Governance & Community

---

### 12.1 Decentralized Governance Model

SAIZ is committed to a progressive transition toward full community governance. Governance rights are proportional to SAIZ token holdings. The governance framework enables token holders to:

- Vote on major project decisions (exchange listings, partnership approvals, fund deployments above defined thresholds).
- Submit Governance Improvement Proposals (GIPs) for community review and vote.
- Oversee treasury management and approve ecosystem fund releases.
- Elect or remove advisory board members via community vote.

### 12.2 Governance Timeline

Governance will be progressively decentralized in line with project maturity:

- Phase 1–2 (2025): Core team governance with community consultation. Governance framework designed and audited.
- Phase 3 (2026): On-chain governance platform launched. Initial community votes conducted for defined proposal types.
- Phase 4 (2027): Full DAO governance. SAIZ Foundation established as independent non-profit oversight entity.

### 12.3 Community Channels

The SAIZ community is cultivated across multiple channels to ensure global accessibility and engagement:

- Official Website: [www.saizone.ai](http://www.saizone.ai)
- Telegram: <https://t.me/saiztoken>
- Instagram: [www.instagram.com/saiz\\_global](http://www.instagram.com/saiz_global)
- HBA Community Forums: Distributed across 20+ countries (Phase 4 target)

## ◆ 13. Legal Disclaimer & Regulatory Compliance

### 13.1 Jurisdiction

The SAIZ Token project is operated by a legal entity registered in the Republic of Korea, subject to Korean law and applicable international regulations governing digital assets, securities, and biotechnology. All SAIZ project activities are conducted in compliance with the requirements of Government Agencies.

### 13.2 Not an Investment or Securities Offering

This Whitepaper does not constitute an offer to sell, a solicitation to buy, or a recommendation to invest in SAIZ tokens or any other securities or financial instruments in any jurisdiction. SAIZ tokens are utility and governance tokens and are not intended to constitute securities, investment contracts, or financial products under the laws of any jurisdiction.

Persons considering participating in the SAIZ token sale are strongly advised to:

- Consult independent legal, financial, tax, and regulatory advisors before making any investment decision.
- Carefully assess their personal financial situation, risk tolerance, and investment objectives.
- Review all applicable laws and regulations in their jurisdiction regarding the purchase, holding, and trading of digital assets.

### 13.3 Risk Factors

Participation in the SAIZ token ecosystem involves significant risks, including but not limited to:

- **Regulatory Risk:** Digital asset regulation is evolving globally. Changes in laws or regulations in any jurisdiction may adversely affect the value, utility, or legality of SAIZ tokens.
- **Technology Risk:** Blockchain technology and smart contracts are subject to potential bugs, exploits, and technical failures. Despite independent security audits, no system can be guaranteed to be entirely free of vulnerabilities.
- **Market Risk:** Digital asset markets are highly volatile. The price of SAIZ tokens may fluctuate significantly, and participants may lose some or all of the value of their holdings.
- **Commercial Risk:** The successful commercialization of the oral antibody product in India and other Asian markets depends on regulatory approvals, commercial execution, and partnership performance — none of which can be fully guaranteed.
- **Liquidity Risk:** Secondary market trading of SAIZ tokens may be limited, particularly in early project phases. Token holders may not be able to sell their tokens at any given time at a favorable price.
- **Concentration Risk:** A significant portion of SAIZ's initial revenue model is dependent on the Loa Biopharm licensing partnership. Disruption of this partnership could adversely affect the ecosystem.

### **13.4 Forward-Looking Statements**

This Whitepaper contains forward-looking statements, including projections, plans, timelines, and expectations regarding the SAIZ project and ecosystem. These statements are based on current beliefs, assumptions, and expectations and are subject to significant uncertainties and risks. Actual results may differ materially from those described in forward-looking statements. SAIZ undertakes no obligation to update or revise any forward-looking statements.

### **13.5 KYC / AML Compliance**

All participants in the SAIZ token public sale will be required to complete Know Your Customer (KYC) identity verification and Anti-Money Laundering (AML) screening procedures prior to purchase. SAIZ reserves the right to refuse participation to any individual or entity who fails to meet compliance requirements or who is located in a jurisdiction where digital asset sales are prohibited or restricted.

### **13.6 Restricted Jurisdictions**

SAIZ tokens are not offered to, and may not be purchased by, persons located in or residents of jurisdictions where such activities are prohibited by law, including but not limited to the United States, Canada (certain provinces), China, and any jurisdiction subject to international sanctions. Participants are solely responsible for ensuring their participation complies with applicable local laws.

## ◆ 14. Contact & Community

The SAIZ team is committed to full transparency and open communication with our global community. We welcome inquiries from investors, partners, healthcare organizations, media, and blockchain communities.

Channel	Details
Official Website	<a href="http://www.saizone.ai">www.saizone.ai</a>
Email — General Inquiries	<a href="mailto:info@saizone.ai">info@saizone.ai</a>
Email — Investor Relations	<a href="mailto:investors@saizone.ai">investors@saizone.ai</a>
Email — Partnership Inquiries	<a href="mailto:partners@saizone.ai">partners@saizone.ai</a>
Telegram (Official)	<a href="https://t.me/saiztoken">https://t.me/saiztoken</a>
Instagram	<a href="http://www.instagram.com/saiz_global">www.instagram.com/saiz_global</a>
Blockchain Partner	Cofinex.io
Technology Partner	Loa Biopharm — <a href="http://loabiopharm.com">loabiopharm.com</a>
Registered Jurisdiction	Republic of Korea
Whitepaper Version	v1.0 — 2025

### IMPORTANT NOTICE

This Whitepaper is provided for informational purposes only. It does not constitute legal, financial, tax, or investment advice. The SAIZ project, its tokens, and this document are subject to change without notice. Participation in the SAIZ token ecosystem is entirely at the participant's own risk. Past performance of digital assets is not indicative of future results. Always conduct your own due diligence.

© 2025 SAIZ Token Project · Republic of Korea · All Rights Reserved

**[www.saizone.ai](http://www.saizone.ai)**